[go: up one dir, main page]

YU66100A - N-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat - Google Patents

N-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat

Info

Publication number
YU66100A
YU66100A YU66100A YU66100A YU66100A YU 66100 A YU66100 A YU 66100A YU 66100 A YU66100 A YU 66100A YU 66100 A YU66100 A YU 66100A YU 66100 A YU66100 A YU 66100A
Authority
YU
Yugoslavia
Prior art keywords
methoxyethoxy
bis
ethynylphenylamino
monohydrate
quinazolinamine mesylate
Prior art date
Application number
YU66100A
Other languages
English (en)
Inventor
John Meldrum Douglas
Timothy Norris
William Jeffrey Raggon
Paul Dinos Santafianos
Mysore Ravi Shanker
Original Assignee
Osi Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharmaceuticals Inc. filed Critical Osi Pharmaceuticals Inc.
Publication of YU66100A publication Critical patent/YU66100A/sh
Publication of RS50081B publication Critical patent/RS50081B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ovaj pronalazak se odnosi na anhidrovane i hidratisane oblike N-(3-etinilfenil)-6,7-bis(2-metoksietoksi)-4-hinazolinamin mezilata. Ovaj pronalazak se takodje odnosi i na farmaceutske preparate koji sadrže N-(3-etinilfenil)-6,7-bis(2-meoksietoksi)-4-hinazolinamin mezilat i na upotrebu anhidrovanog ili hidratisanog oblika N-(3-etinilfenil)-6,7-bis(2-metoksietoksi)-4-hinazolinamin mezilata za proizvodnju leka korisnog u lečenju hiperproliferativnog obljenja kod sisara.[The present invention relates to the anhydrous and hydrate forms of N- (3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)4- quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N- (3-ethynylphenyl)-6,7-bis(2- methoxyethoxy) -4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N- (3-ethynylphenyl)-6,7- bis(2-methoxyethoxy)-4-quinazolinamine mesylate.
YUP-661/00A 1998-04-29 1999-04-08 N-(3-etinilfenilamino)-6,7-bis (2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat RS50081B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29

Publications (2)

Publication Number Publication Date
YU66100A true YU66100A (sh) 2003-07-07
RS50081B RS50081B (sr) 2009-01-22

Family

ID=22178359

Country Status (41)

Country Link
EP (1) EP1076652B1 (sh)
JP (1) JP4652569B2 (sh)
KR (1) KR100668412B1 (sh)
CN (2) CN101219999A (sh)
AP (1) AP1252A (sh)
AR (1) AR018201A1 (sh)
AT (1) ATE295839T1 (sh)
AU (1) AU759691C (sh)
BR (1) BR9910025A (sh)
CA (1) CA2330447C (sh)
CO (1) CO5060467A1 (sh)
CZ (1) CZ298230B6 (sh)
DE (1) DE69925366T2 (sh)
DZ (1) DZ2777A1 (sh)
EA (1) EA002836B1 (sh)
EG (1) EG24000A (sh)
ES (1) ES2238825T3 (sh)
GT (1) GT199900063A (sh)
HN (1) HN1999000057A (sh)
HU (1) HU227569B1 (sh)
ID (1) ID27198A (sh)
IL (1) IL139172A0 (sh)
MA (1) MA26624A1 (sh)
ME (1) MEP42008A (sh)
MX (1) MXPA00010610A (sh)
MY (1) MY136033A (sh)
NO (1) NO317301B1 (sh)
NZ (1) NZ508154A (sh)
OA (1) OA11769A (sh)
PA (1) PA8471001A1 (sh)
PE (1) PE20000441A1 (sh)
PL (1) PL196940B1 (sh)
RS (1) RS50081B (sh)
SA (1) SA99200216B1 (sh)
TN (1) TNSN99079A1 (sh)
TR (1) TR200003166T2 (sh)
TW (1) TWI248437B (sh)
UA (1) UA60363C2 (sh)
UY (1) UY26099A1 (sh)
WO (1) WO1999055683A1 (sh)
ZA (1) ZA992972B (sh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
KR101126560B1 (ko) 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
EP1680426B1 (en) 2003-06-10 2007-09-19 F. Hoffmann-La Roche Ag 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US8080577B2 (en) 2004-05-06 2011-12-20 Bioresponse, L.L.C. Diindolylmethane formulations for the treatment of leiomyomas
WO2006083458A2 (en) 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
WO2008057253A2 (en) 2006-10-27 2008-05-15 Bioresponse, L.L.C. Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
KR20140069232A (ko) * 2007-04-04 2014-06-09 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
EP2213665A1 (en) 2007-08-17 2010-08-04 Hetero Drugs Limited Erlotinib hydrochloride
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
CN102438995B (zh) 2009-03-26 2014-12-17 兰贝克赛实验室有限公司 厄洛替尼或其药学上可接受的盐的制备工艺
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
GT199900063A (es) 2000-10-20
EP1076652B1 (en) 2005-05-18
KR100668412B1 (ko) 2007-01-12
MXPA00010610A (es) 2002-07-02
CN101219999A (zh) 2008-07-16
AU2850999A (en) 1999-11-16
AR018201A1 (es) 2001-10-31
EG24000A (en) 2008-03-19
ES2238825T3 (es) 2005-09-01
TNSN99079A1 (fr) 2005-11-10
CA2330447A1 (en) 1999-11-04
MEP42008A (en) 2011-02-10
TWI248437B (en) 2006-02-01
NO20005453D0 (no) 2000-10-27
PL196940B1 (pl) 2008-02-29
MY136033A (en) 2008-07-31
PL343766A1 (en) 2001-09-10
PA8471001A1 (es) 2000-09-29
BR9910025A (pt) 2000-12-26
DE69925366D1 (de) 2005-06-23
OA11769A (en) 2005-07-25
CA2330447C (en) 2009-06-30
ZA992972B (en) 2000-10-30
IL139172A0 (en) 2001-11-25
JP2002513009A (ja) 2002-05-08
CO5060467A1 (es) 2001-07-30
PE20000441A1 (es) 2000-05-23
CN1298396A (zh) 2001-06-06
EA200001112A1 (ru) 2001-04-23
HUP0101818A3 (en) 2002-05-28
TR200003166T2 (tr) 2001-02-21
AP1252A (en) 2004-02-25
WO1999055683A1 (en) 1999-11-04
HUP0101818A1 (hu) 2002-03-28
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
ID27198A (id) 2001-03-08
CZ20003974A3 (en) 2001-05-16
NO20005453L (no) 2000-12-20
AP9901523A0 (en) 1999-06-30
HN1999000057A (es) 1999-09-29
EA002836B1 (ru) 2002-10-31
NZ508154A (en) 2003-07-25
ATE295839T1 (de) 2005-06-15
MA26624A1 (fr) 2004-12-20
SA99200216B1 (ar) 2006-06-04
RS50081B (sr) 2009-01-22
EP1076652A1 (en) 2001-02-21
NO317301B1 (no) 2004-10-04
AU759691C (en) 2004-04-29
HU227569B1 (en) 2011-08-29
JP4652569B2 (ja) 2011-03-16
CZ298230B6 (cs) 2007-08-01
HK1037180A1 (en) 2002-02-01
UA60363C2 (uk) 2003-10-15
UY26099A1 (es) 2001-12-28
AU759691B2 (en) 2003-04-17
KR20010078710A (ko) 2001-08-21

Similar Documents

Publication Publication Date Title
YU66100A (sh) N-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat
YU34202A (sh) Stabilni polimorf n-(3-etinilfenilamino)-6,7-bis(2- metoksietoksi)-4-kvinazolinamin hidrohlorida, postupci proizvodnje i njegova farmaceutska upotreba
MXPA04004219A (es) Derivados de quinazolina como agentes antitumorales.
MXPA05007831A (es) Preparacion de quinazolinas substituidas.
AP2004003058A0 (en) Quinazoline derivatives for the treatment of abnormal cell growth.
MXPA04004220A (es) Derivados de quinazolina como agentes antitumorales.
MY138851A (en) Quinazoline derivatives
ATE353888T1 (de) Chinazolinderivate
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
UA89038C2 (en) Pyrrolotriazine compounds as kinase inhibitors
YU84603A (sh) Novi inhibitori tirozin kinaze
TW200512205A (en) Quinazoline derivatives
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
SI1597239T1 (sl) Polimorf od (6,7-bis(2-metoksi-etoksi)-kinazolin-4-il)-(3e)
PL367682A1 (en) Dolastatin 10 derivatives
TW200420565A (en) C-6 modified indazolylpyrrolotriazines
AP2004003059A0 (en) Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
GB0309850D0 (en) Quinazoline derivatives
MXPA05000781A (es) Compuesto antitumor y usos terapeuticos del mismo.
MXPA06003161A (es) Derivados de quinazolina.
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
UA90659C2 (ru) Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ